(Reuters) - Pfizer Inc (N:PFE) said on Friday it signed a multi-year agreement to make Gilead Sciences Inc 's (O:GILD) antiviral drug remdesivir in a bid to ramp up supply of...
Investing.com -- Here is a roundup of regulatory news releases from the London Stock Exchanges on Thursday, 7th November. Please refresh for updates.Rolls-Royce (LON:RR) said it...
Vaccines manufactured by three groups have so far been approved in the UK. They include:AstraZeneca (LON:AZN) (NASDAQ:AZN)/ Oxford University;BioNTech (NASDAQ:BNTX) / Pfizer...
Recent positive news about a COVID-19 vaccine has put the limelight on health-care and pharmaceutical companies, especially BioNTtech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA) and...
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates through three segments, such as Injectables, Generics and Branded. The Injectables business develops and manufactures generic injectable products, which are primarily used in hospitals. The Generics business develops and manufactures oral and other non-injectable generic products. The Branded business develops and manufactures branded generics and markets and sells in-licensed patented products in Middle East/North Africa (MENA). The Company’s products are sold in the retail and hospital markets. It also markets its products in Canada, which includes approximately 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products.